Abstract: A method for determining a response device, a device, and a server are provided. The method includes: obtaining a target probability value of a device as a response device based on a preset probability value strategy subsequent to receiving a voice control signal, the probability value strategy being determined based on response state information of the device to the voice control signal; determining a target signal-to-noise ratio based on the target probability value and a signal-to-noise ratio of the received voice control signal; and determining whether the device is a response device to the voice control signal based on the target signal-to-noise ratio.

Abstract: Disclosed herein are compositions and methods for targeted treatment of liver cancers with Paclitaxel and miR-122. The disclosed composition comprises RNA nanostructure conjugated to a hepatocyte targeting ligand, paclitaxel, and miR-122 for use in intracellular drug delivery to liver cancer cells. The RNA nanoparticle can involve three or more self-assembled synthetic RNA oligonucleotides that form a central core domain and at least three double-stranded arms arranged around the core domain and extending away from the central core domain.

Abstract: A hydraulic system including a secondary pressure regulating transmission control system and a hydraulic power-supply system is provided. The secondary pressure regulating transmission control system includes a first hydraulic control system, a second hydraulic control system, and a third hydraulic control system. An integrated electro-hydraulic actuator of the first hydraulic control system is mounted on a first hydraulic cylinder, the integrated electro-hydraulic actuator of the second hydraulic control system is mounted on a second hydraulic cylinder, and the integrated electro-hydraulic actuator of the third hydraulic control system is mounted on a third hydraulic cylinder. The first hydraulic control system is configured to control a movable arm, the second hydraulic control system is configured to control a stick, and the third hydraulic control system is configured to control a bucket.

Abstract: Provided is a system for electro-hydraulic control of hydraulic pipeline rupture protection based on differential pressure feedback, which relates to the field of hydraulic control technology. The system comprises a hydraulic actuation system and a controller system. The controller system comprises a differential pressure feedback loop and a flow rate diagnostic loop. The differential pressure feedback loop is configured to obtain a flow rate signal within a hydraulic pipeline and determine a proportional signal. The flow rate diagnostic loop is configured to receive the proportional signal, and in response to determining that a duration for which the proportional signal remains outside a threshold range reaches a preset safety duration, cut off an actuating end of the hydraulic actuation system to achieve pipeline rupture protection.

Abstract: A method for determining a response device, a device, and a server are provided. The method includes: obtaining a target probability value of a device as a response device based on a preset probability value strategy subsequent to receiving a voice control signal, the probability value strategy being determined based on response state information of the device to the voice control signal; determining a target signal-to-noise ratio based on the target probability value and a signal-to-noise ratio of the received voice control signal; and determining whether the device is a response device to the voice control signal based on the target signal-to-noise ratio.

Abstract: Disclosed herein is a therapeutics structure containing a motion element, an methotrexate (MTX), N—[N—[(S)-1,3-dicarboxypropyl]carbamoyl]-(S)-lysine (DCL), or UAMC-1110 ligand, and a plurality of drugs selected from the group consisting of camptothecin (CPT), paclitaxel (PTX), podophyllotoxin (PTOX), 7-Ethyl-10-hydroxycamptothecin (SN38), BMS1, BMS8, BMS27, BMS242, LY294002, PI3K-IN-20, and methotrexate (MTX).

Abstract: Disclosed herein are compositions and methods for targeted treatment of liver cancers with Paclitaxel and miR-122. The disclosed composition comprises RNA nanostructure conjugated to a hepatocyte targeting ligand, paclitaxel, and miR-122 for use in intracellular drug delivery to liver cancer cells. The RNA nanoparticle can involve three or more self-assembled synthetic RNA oligonucleotides that form a central core domain and at least three double-stranded arms arranged around the core domain and extending away from the central core domain.